Medtronic (MDT) announced U.S. FDA clearance of the Stealth AXiS surgical system for cranial and ear, nose, and throat procedures. Cleared for spine procedures in February, the Stealth AXiS surgical system unifies surgical planning, navigation, and robotics into a single intelligent system to support surgeons with greater precision and real-time insights during complex procedures. This clearance reinforces Medtronic’s strategy to deliver connected technologies that support surgeons across multiple specialties on a single platform.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic: Temporary MiniMed Charge Leaves Multi‑Year Earnings Growth and Buy Thesis Intact
- Medtronic Cuts Fiscal 2026 EPS Outlook After MiniMed Charges
- Medtronic cuts FY26 EPS view to $5.50-$5.54 from $5.62-$5.66, consensus $5.64
- Medtronic, Merit Medical enter pact to offer new, FDA-cleared ViaVerte system
- Medtronic gets FDA approval for expanded indication for OmniaSecure